Most people with asthma are able to control their symptoms by using inhaled medicines each day. But for some people with severe asthma, inhaled medicines are not enough to keep symptoms under control.

Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...

Five years after its first FDA approval in eczema, Sanofi’s Dupixent is still blazing a trail in inflammatory diseases. That’s the evaluation of Bill Sibold, Sanofi’s global head of specialty care, ...

After hitting a home run with trial results for Dupixent in chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron are circling the bases, considering an exciting future with another ...

Please provide your email address to receive an email when new articles are posted on . These studies are the first published using Dupixent in this indication. The primary endpoint was met by up to ...

Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ...

Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

Sanofi SNY and partner Regeneron REGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of ...

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match ...